Ankylosing Spondylitis

Global Ankylosing Spondylitis Market to Reach US$8.1 Billion by 2030

The global market for Ankylosing Spondylitis estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. TNF Inhibitors Drug Class, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the NSAIDs Drug Class segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Ankylosing Spondylitis market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Ankylosing Spondylitis Market - Key Trends & Drivers Summarized

Why Is Ankylosing Spondylitis Becoming a Critical Global Health Concern?

Ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is gaining recognition as a significant global health concern due to its debilitating nature and long-term impact on quality of life. AS primarily affects young adults, with symptoms often beginning in the late teens or early twenties. The progressive nature of the disease, characterized by chronic pain, stiffness, and potential spinal fusion, underscores the need for effective therapeutic interventions to manage symptoms and prevent complications. Moreover, the rising prevalence of ankylosing spondylitis worldwide has led to increased demand for targeted treatment options. While the exact cause of AS remains unclear, genetic predisposition, particularly the presence of the HLA-B27 gene, has been identified as a major risk factor. This has prompted advancements in precision medicine approaches, enabling tailored treatment strategies for individuals with AS. Additionally, the societal and economic burden of the disease, including loss of productivity and healthcare costs, has heightened the focus on improving access to effective therapies.

What Advancements Are Driving the Development of AS Treatments?

The treatment landscape for ankylosing spondylitis has evolved significantly, driven by advancements in biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Tumor necrosis factor (TNF) inhibitors, such as adalimumab and infliximab, have been pivotal in transforming the management of AS by reducing inflammation, slowing disease progression, and improving patient outcomes. The introduction of interleukin (IL)-17 inhibitors, including secukinumab and ixekizumab, has further expanded treatment options, particularly for patients who do not respond to TNF inhibitors. Innovations in drug delivery systems, such as self-administered subcutaneous injections and extended-release formulations, have improved patient compliance and convenience. Furthermore, advancements in diagnostic tools, including magnetic resonance imaging (MRI) and genetic testing, are facilitating earlier detection of AS, enabling timely intervention and better disease management. Ongoing research into novel therapeutic targets, such as Janus kinase (JAK) inhibitors, holds promise for expanding the range of effective treatment options in the near future.

How Are Regional Dynamics Influencing Market Growth?

The ankylosing spondylitis market exhibits significant regional variations, influenced by differences in disease prevalence, healthcare infrastructure, and access to advanced treatments. North America dominates the market, driven by a high prevalence of autoimmune diseases, robust healthcare systems, and substantial investments in research and development. The region also benefits from favorable reimbursement policies and widespread availability of advanced biologic therapies. Europe follows closely, with a strong focus on early diagnosis and the integration of innovative treatments into standard care protocols. Countries such as Germany, the UK, and France have well-established rheumatology networks, ensuring better disease management and patient outcomes. In the Asia-Pacific region, the market is expanding rapidly due to increasing disease awareness, improving healthcare access, and rising disposable incomes. Emerging economies such as China and India are witnessing growing adoption of biologic therapies, supported by government initiatives to enhance healthcare infrastructure. Meanwhile, Latin America and the Middle East are gradually embracing advanced treatments, although challenges related to affordability and awareness persist.

What Is Driving Growth in the Ankylosing Spondylitis Market?

The growth in the ankylosing spondylitis market is driven by several factors, including the rising prevalence of autoimmune and inflammatory diseases, advancements in biologic therapies, and increasing awareness of the importance of early diagnosis. The growing adoption of TNF inhibitors and IL-17 inhibitors as first-line treatments has significantly improved patient outcomes, fueling market expansion. Additionally, the development of next-generation therapies, including JAK inhibitors and other novel biologics, is addressing unmet needs in AS management. Consumer demand for more convenient and effective treatment options, such as self-administered injections, has spurred innovation in drug delivery systems. Regional government initiatives to improve healthcare access and affordability, particularly in emerging markets, are further driving the adoption of advanced therapies. Moreover, the integration of digital health tools, including telemedicine and remote monitoring, is facilitating better disease management and treatment adherence. These factors collectively highlight the robust growth trajectory of the ankylosing spondylitis market and its critical role in addressing the global burden of this chronic condition.

SCOPE OF STUDY:

The report analyzes the Ankylosing Spondylitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (TNF Inhibitors Drug Class, NSAIDs Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie, Inc.
• Akeso Biopharma Co., Ltd.
• Amgen, Inc.
• Coherus Biosciences, Inc.
• Eli Lilly and Company
• Johnson & Johnson Innovative Medicine UK
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc.
• Trinity Biotech PLC
• UCB SA
• ViennaLab Diagnostics GmbH
• Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.